English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 August 2022, 18:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Bhd
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU
Parties to look for collaborations in practice-based education, research and knowledge exchange and R&D

PETALING JAYA, Malaysia, Aug 18, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad's (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.


En. Azri Azerai, Executive Director of Malaysian Genomics

Datin Dr Maya, Chief Executive Officer of MAHSA Health

Malaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years. Since then, Malaysian Genomics has expanded its offerings in other important areas in the healthcare and wellness that include cancer immunotherapy, cell manufacturing services and kidney dialysis. Malaysian Genomics continues to strive to provide the latest in precautionary, preventive and curative healthcare services for its local and worldwide customers.

MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.

Encik Azri Azerai, Executive Directorof Malaysian Genomics said, "We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration. By providing industry inputs and insights to MAHSA, we hope to benefit students at MAHSA with the tremendous promise that various healthcare sciences have to offer for all."

"Through this collaboration we also hope to identify opportunities to improve the delivery of integrated, holistic primary healthcare services, including genetic screening services to improve the lives of individuals in the long run."

Datin Dr Maya, CEO of MAHSA Health, with her double expertise in health and wellness services, and education industry, said, "Passion is the greatest asset we each have. The main idea of MAHSA Health is to improve the quality of life in providing health care and wellness services to our community. We are a team-based healthcare that provides comprehensive medical care to patients with the goal of obtaining maximized health outcomes."

"Through this collaboration, we foresee opportunities and collaborative efforts in many areas, both in health care and education industry in providing an ecosystem of teaching, training, and producing services to the country nationwide."

The MoU is a framework through which MGRC Therapeutics and MAHSA Health can explore opportunities for health and wellness-related services; create opportunities for students' clinical placement, internship and employment; identify opportunities for conducting collaborative research and development (R&D); and create opportunities in training, seminars and conferences.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Topic: Press release summary
Source: Malaysian Genomics Resource Centre Bhd

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm, Local Biz
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Malaysian Genomics Resource Centre Bhd Related News
Aug 29, 2023 13:00 HKT/SGT
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals
May 15, 2023 18:00 HKT/SGT
Malaysian Genomics Inks Agreement in Expansion to Bangladesh
Feb 27, 2023 13:00 HKT/SGT
Malaysian Genomics to Boost Play on the Football Pitch
Feb 24, 2023 17:30 HKT/SGT
Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Feb 24, 2023 13:30 HKT/SGT
Malaysian Genomics to Collaborate on Cannabinoid R&D
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575